# Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

> **NCT04826003** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 54 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** RO7122290
- **DRUG:** Cibisatamab
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04826003
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-14
- **Primary completion:** 2024-11-11
- **Final completion:** 2024-11-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04826003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04826003, "Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04826003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*